BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 10829039)

  • 1. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.
    Allgayer H; Babic R; Gruetzner KU; Tarabichi A; Schildberg FW; Heiss MM
    J Clin Oncol; 2000 Jun; 18(11):2201-9. PubMed ID: 10829039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Schildberg FW; Heiss MM
    Clin Exp Metastasis; 1998 Jan; 16(1):62-73. PubMed ID: 9502078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
    Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
    Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Wilhelm Schildberg F; Heiss MM
    Cancer; 1997 Jul; 80(2):179-87. PubMed ID: 9217027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
    Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
    Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
    Allgayer H; Babic R; Beyer BC; Grützner KU; Tarabichi A; Schildberg FW; Heiss MM
    Oncology; 1998; 55(2):152-60. PubMed ID: 9499190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer.
    Lian PL; Liu Z; Yang GY; Zhao R; Zhang ZY; Chen YG; Zhuang ZN; Xu KS
    World J Gastroenterol; 2016 Apr; 22(14):3852-9. PubMed ID: 27076771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
    Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
    J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao E; Han D; Yu Z; Fan E; Li Y; Zhou Z
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):599-602. PubMed ID: 15515548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
    Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
    World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine and serine proteases in gastric cancer.
    Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
    Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.